Compliance officers from the life sciences industry joined together recently to discuss how the COVID-19 pandemic has changed the ways we live and work, and how those changes have impacted the life sciences industry as a whole and will continue to do so in the future. From there, leaders discussed ways that life sciences companies can find a “new normal,” moving forward in the various roles that Ethics and Compliance must take relative to three critical topics. Guidehouse has summarized these key considerations below:
A public health crisis can impact delivery of care to current and future patients. The pandemic also potentially makes each of us a COVID-19 patient. In this intersection, Ethics and Compliance officers must:
Business as usual is not possible anymore. As the business adjusts in order to continue to meet the needs of its customers, Ethics and Compliance officers must: